Progression Free Survival and Overall Survival in NADIM II Study — Dr. Mariano Provencio
Recorded Monday August 8th @ WCLC 2022 in Vienna, Austria
Видео Progression Free Survival and Overall Survival in NADIM II Study — Dr. Mariano Provencio канала Oncoletter
Видео Progression Free Survival and Overall Survival in NADIM II Study — Dr. Mariano Provencio канала Oncoletter
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![Adjuvante endokrine Therapie bei prä- und postmenopausalen Patientinnen J. Huober, U. Nitz](https://i.ytimg.com/vi/mj_EQ-ZwExE/default.jpg)
![ASCO Annual Meeting 2022 - Press Conference - Monday, June 6](https://i.ytimg.com/vi/vSzns4o8CJk/default.jpg)
![Interview with Prof. Dr. med. Reinhard Dummer, Zürich - COBRIM-study](https://i.ytimg.com/vi/TXLykauIOPE/default.jpg)
![Dr. med. A. Müller: To the Bone: Wie ist das nun mit Prolia, Aclasta und Zometa?](https://i.ytimg.com/vi/Tjn6Mxe1ryY/default.jpg)
![The Issue of Steroid Use with Immune Checkpoint Inhibition: Alessandra Curioni](https://i.ytimg.com/vi/2IUGqzcD3I4/default.jpg)
![ASCO23 - LBA4: SWOG S1826, Nivolumab(N)-AVD vs. Brentuximab Vedotin(BV)-AVD in Advanced Stage (A...](https://i.ytimg.com/vi/d1jn1-q9QYQ/default.jpg)
![Prof. Dr. med. Mathias Warm](https://i.ytimg.com/vi/2JlALZ2GEwE/default.jpg)
![F. Honecker: Herausforderungen bei der Behandlung geriatrischer Patienten](https://i.ytimg.com/vi/QBnbks5h2vI/default.jpg)
![SABCS2020: Highlights beim triple negativen Mammakarzinom](https://i.ytimg.com/vi/iWLHNiFBpX4/default.jpg)
![Session 7: Extent of surgery post neoadjuvant – setting: Estimating the extent of surgery (Flori...](https://i.ytimg.com/vi/q0avjC9yBZw/default.jpg)
![ASCO23 - LBA1: INDIGO: Vorasidenib versus placebo in patients with residual or recurrent grade 2...](https://i.ytimg.com/vi/nwzEb4iLTpc/default.jpg)
![SABCS 2022: Prof. Dr. med. Wolfgang Janni, Ulm Stellenwert von ctDNA](https://i.ytimg.com/vi/PjTNEX8_hRw/default.jpg)
![FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell](https://i.ytimg.com/vi/yz5ttntL6QY/default.jpg)
![Evaluation of TMB in KEYNOTE-189: Pembrolizumab + CT vs Placebo + CT for Nonsquamous NSCLC](https://i.ytimg.com/vi/qtaQLhIanX8/default.jpg)
![Discussion of tissue engineered bronchus](https://i.ytimg.com/vi/yYnSdqqHjAA/default.jpg)
![Prof. Volkmar Müller, Renate Haidinger, Brustkrebs Deutschland e.v., Prof. Christian Jackisch: K...](https://i.ytimg.com/vi/8-MRl97fvpc/default.jpg)
![#ASCO21 - Oleg Gluz: WSG-ADAPT HR+/HER2- Ergebnisse in der Hochrisikogruppe](https://i.ytimg.com/vi/fRgo9pQRXgA/default.jpg)
![Strahlentherapie der Brust – Ist weniger mehr?](https://i.ytimg.com/vi/2ZwbIDYK7Ko/default.jpg)
![Dr. med. S. Riniker: Endokrine Therapie: Tradition und Moderne](https://i.ytimg.com/vi/L3aCnWXQxlM/default.jpg)
![Summary of most important changes AGO breast cancer guidelines 2021](https://i.ytimg.com/vi/SE6j8rgrBhM/default.jpg)
![ASCO 2015: Die Highlights zum Brustkrebs von Experten diskutiert](https://i.ytimg.com/vi/jLBMTYTMyfc/default.jpg)